

**REMARKS**

Claim 1 is being amended to include within its scope the language of claims 2-6, which have been cancelled without prejudice.

Multiply dependent claims 16 and 20 (and all claims dependent therefrom) have been amended to be singly dependent, thereby removing all proper and improper multiple dependencies.

New claims have been added, primarily to include embodiments of expression vectors, pharmaceutical compositions and methods based on the nucleic acid recited in claim 10 (the HPV E6 DNA/polypeptide). These embodiments were included in the original multiply dependent claims. Further, claims 15, 28 and 39 are cancelled without prejudice to reduce extra claim fees.


There are now a total of 37 claims pending in the application, as follows:

**Claims 1, 7-14, 16-27, 29-38 and 40-45 (of which 41-45 are new).**

None of the amendments or new claims introduces new matter. Examination of these claims on the merits and their allowance are respectfully requested.

Dated: November 7, 2005

Respectfully submitted,

By   
Shmuel Livnat  
Registration No.: 33,949  
MCKENNA LONG & ALDRIDGE LLP  
1900 K Street, N.W.  
Washington, DC 20006  
(202) 496-7500  
Attorneys for Applicant